OncoMatch/Clinical Trials/NCT05124002
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Is NCT05124002 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Recombinant Human Adenovirus Type 5 and HAIC of FOLFOX for cholangiocarcinoma, intrahepatic.
Treatment: Recombinant Human Adenovirus Type 5 · HAIC of FOLFOX — Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor effects on liver cancer. This study aims to further verify the effect and safety of recombinant human adenovirus type 5 combined with HAIC in the treatment of intrahepatic mass-forming cholangiocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Prior therapy
Cannot have received: oncolytic virus (T-VEC)
Previous treatment with oncolytic viruses (such as T-VEC)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 3.5 × 10^9/l; platelets ≥ 125 × 10^9/l; hemoglobin ≥ 8 g/dl
Kidney function
creatinine ≤ 1.5 uln
Liver function
bilirubin ≤ 3 uln, alt/ast ≤ 2.5 uln; alt/ast in the presence of liver metastases ≤ 5 uln
Cardiac function
lvef > 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify